Skip to main content

Table 1 Clinical characteristics of HBsAg-positive and -negative patients with diffuse large B-cell lymphoma

From: Clinicopathological and prognostic features of hepatitis B virus-associated diffuse large B-cell lymphoma: a single-center retrospective study in China

Factors

HBsAg-positive patients (n = 127)

HBsAg-negative patients (n = 293)

P value

No

%

No

%

Age > 60

22

17.3

97

33.1

0.001*

Gender

    

0.116*

 Male

79

62.2

158

53.9

 

 Female

48

37.8

135

46.1

 

Bulky mass (≥ 7.5 cm)

22

17.3

52

17.7

0.916*

Special sites involvement

     

 Liver

6

4.7

10

3.4

0.519*

 Spleen

28

22.0

19

6.5

 < .001*

 Stomach

11

8.6

34

11.6

0.371*

 Intestinal

3

2.3

33

11.2

0.003*

 Waldeyer’ string

26

20.5

71

24.2

0.401*

 Bone

9

7.1

12

4.1

0.196*

Performance status

    

0.425*

 0–1

115

90.6

272

92.8

 

 2–4

12

9.4

21

7.2

 

B symptoms present

28

22.0

76

26.0

0.396*

Elevated LDH

59

46.5

135

46.1

0.943*

Ann Arbor stage

    

0.028*

 I–II

55

43.3

161

54.9

 

 III–IV

72

56.7

132

45.1

 

Extra-nodal sites ≥ 2

22

17.3

49

16.7

0.880*

IPI score

    

0.653*

 0–1

103

81.1

232

79.2

 

 3–5

24

18.9

61

20.8

 

Use of rituximab

60

47.2

143

48.8

0.769*

Response to chemotherapy

    

0.300†

 Complete response

78

61.4

196

66.9

 

 Partial response

40

31.5

83

28.3

 

 Stable disease

1

0.8

4

1.4

 

 Progressive disease

7

5.5

10

3.4

 

 Not available

1

0.8

0

0.0

 
  1. IPI International Prognostic Index, LDH lactate dehydrogenase
  2. *χ2 test for independence in HBsAg-positive compared with HBsAg-negative patients
  3. †Fisher exact test for independence in HBsAg-positive compared with HBsAg-negative patients